Exploration of Targeted Anti-tumor Therapy

Table 3. Mutations in kinase domains

Chr	Position	REF	ALT	Gene	Protein	Effect	CADD
1	59321726	G	T	FGGY	p.Trp59Cys	missense_variant	29.7
1	64177651	G	T	ROR1	p.Cys537Phe	missense_variant	25.6
7	151057136	G	A	CDK5	p.Ala21Val	missense_variant	29.5
4	86101117	G	A	MAPK10	p.Pro222Leu	missense_variant	27.8
6	7402834	G	A	RIOK1	p.Cys235Tyr	missense_variant	31
1	162500036	G	T	UHMK1	p.Ser117Ile	missense_variant	28.5
3	142496516	C	G	ATR	p.Asp1915His	missense_variant	25.4
17	28122673	G	T	NLK	p.Val177Phe	missense_variant	27.9
19	40238013	G	C	AKT2	p.Leu263Val	missense_variant	25.1
6	115942559	C	G	FRK	p.Cys458Ser	missense_variant	25.3
9	127789200	A	G	CDK9	p.Tyr259Cys	missense_variant	28.5
5	56883589	G	C	MAP3K1	p.Trp1243Cys	missense_variant	32
19	18123365	G	T	MAST3	p.Arg183Leu	missense_variant	26.4
1	204440257	C	A	PIK3C2B	p.Trp1105Leu	missense_variant	29.1
10	103999254	G	T	SLK	p.Met241Ile	missense_variant	26
2	147918462	T	A	ACVR2A	p.Phe278Ile	missense_variant	25.1
2	172564574	T	A	PDK1	p.Ile181Asn	missense_variant	25.8
1	179117461	C	T	ABL	p.Asp427Asn	missense_variant	28.4
1	205528150	C	G	CDK18	p.Ser349Cys	missense_variant	28.8
7	100807468	C	A	EPHB4	p.Arg744Leu	missense_variant	29.4
6	10803770	C	G	MAK	p.Glu205Gln	missense_variant	25.3
16	23695909	CС	AA	ERN2	p.Gly532Leu	missense_variant	25.4
7	137645473	T	A	DGKI	p.Lys268Met	missense_variant	34
8	140746862	T	C	PTK2	c.1820-2 T > C	splice_acceptor_variant	33
16	18850461	C	A	SMG1	p.Asp1687Tyr	missense_variant	27.5
7	140673943	C	A	ADCK2	p.Pro205Thr	missense_variant	25.6
13	26337623	C	T	CDK8	p.Ser62Leu	missense_variant	29.9
15	98957103	G	T	IGF1R	p.Met1255Ile	missense_variant	29.1
18	21045409	C	A	ROCK1	p.Gly158Val	missense_variant	25.8
4	106250454	C	A	TBCK	p.Asp208Tyr	missense_variant	25.5
3	38397157	A	G	XYLB	p.His452Arg	missense_variant	25.2
11	67434052	G	A	RPS6KB2	p.Val322Met	missense_variant	26.5
2	200853964	A	G	CLK1	p.Leu459Ser	missense_variant	27.3
21	44325220	G	T	PFKL	p.Gly649Cys	missense_variant	26.7
4	78844976	T	C	BMP2K	p.Phe199Leu	missense_variant	28.1
8	27828135	C	T	PBK	p.Gly41Asp	missense_variant	25.7
9	4719192	C	A	AK3	p.Trp129Cys	missense_variant	32
1	32275576	T	G	LCK	p.Phe129Val	missense_variant	31
22	20729351	C	A	PI4KA	p.Trp1548Cys	missense_variant	28.5
9	99144879	G	A	TGFBR1	p.Gly378Glu	missense_variant	29.4
3	142493161	C	T	ATR	p.Glu2017Lys	missense_variant	29.2
15	50574399	C	G	TRPM7	p.Arg1728Thr	missense_variant	25.6
2	241499292	G	A	STK25	p.Pro184Ser	missense_variant	28.4
1	46023823	G	C	MAST2	p.Lys541Asn	missense_variant	26.5
9	130854948	G	T	ABL	p.Arg153Leu	missense_variant	29
7	151077742	G	T	FASTK	p.Leu360Met	missense_variant	25.5
19	45778550	T	C	DMPK	p.Tyr175Cys	missense_variant	29.8
19	17835206	C	A	JAK3	p.Gly642Cys	missense_variant	26.6
18	42057984	G	T	PIK3C3	p.Gly789Cys	missense_variant	31
2	219481341	C	G	SPEG	p.Arg1803Gly	missense_variant	26
19	1220692	G	T	STK11	p.Asp237Tyr	missense_variant	32
5	178612457	A	G	CLK4	p.Leu337Ser	missense_variant	29.4
11	67433445	A	C	RPS6KB2	p.Lys302Gln	missense_variant	25.5

Return to article view

Chr: chromosome; REF: reference allele; ALT: alternative allele; CADD: combined annotation dependent depletion

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1002330_sup_1.xlsx.

Declarations

Author contributions

EVP: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft, Writing—review & editing, Visualization. RSM, FAZ, ESS, PRK, JOB, and VIT: Investigation. AAR: Investigation, Formal analysis. IVB: Methodology, Formal analysis. ENI: Conceptualization, Writing—original draft, Writing—review & editing, Supervision. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

Evgeny N. Imyanitov who is the Editorial Board Member of Exploration of Targeted Anti-tumor Therapy had no involvement in the decision-making or the review process of this manuscript. Other authors declare that they have no conflicts of interest.

Ethical approval

The study was conducted in accordance with the Declaration of Helsinki 2013 and approved by the local Ethical Committee of N.N. Petrov Institute of Oncology (Approval Code: 753. Approval Date: 31 October 2023).

Consent to participate

Informed consent was obtained from all subjects involved in the study.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This research has been supported by the Russian Science Foundation, grant number [24-45-10014]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, et al. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene. 2013;32:27–38. [DOI] [PubMed]

Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers (Basel). 2021;13:2748. [DOI] [PubMed] [PMC]

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54. [DOI] [PubMed]

Harada G, Yang SR, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol. 2023;20:229–49. [DOI] [PubMed] [PMC]

Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023;7:101. [DOI] [PubMed] [PMC]

Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers—biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18:35–55. [DOI] [PubMed] [PMC]

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–47. [DOI] [PubMed] [PMC]

Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, et al. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. Lung Cancer. 2020;140:46–54. [DOI] [PubMed]

Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al.; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383:944–57. [DOI] [PubMed]

10.

Spagnolo CC, Ciappina G, Giovannetti E, Squeri A, Granata B, Lazzari C, et al. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? Int J Mol Sci. 2023;24:10119. [DOI] [PubMed] [PMC]

11.

Nützinger J, Bum Lee J, Li Low J, Ling Chia P, Talisa Wijaya S, Chul Cho B, et al. Management of HER2 alterations in non-small cell lung cancer—The past, present, and future. Lung Cancer. 2023;186:107385. [DOI] [PubMed]

12.

Imyanitov EN, Preobrazhenskaya EV, Orlov SV. Current status of molecular diagnostics for lung cancer. Explor Target Antitumor Ther. 2024;5:742–65. [DOI] [PubMed] [PMC]

13.

Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20:213. [DOI] [PubMed] [PMC]

14.

Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9. [DOI] [PubMed] [PMC]

15.

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323. [DOI] [PubMed] [PMC]

16.

Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, et al. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature. 2021;600:319–23. [DOI] [PubMed] [PMC]

17.

Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30:1121–6. [DOI] [PubMed] [PMC]

18.

Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, et al. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. JTO Clin Res Rep. 2022;3:100332. [DOI] [PubMed] [PMC]

19.

Song Z, Lv D, Chen SQ, Huang J, Li Y, Ying S, et al. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Clin Cancer Res. 2022;28:461–7. [DOI] [PubMed]

20.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019;25:64–72. [DOI] [PubMed]

21.

Cobleigh MA, Abukheir AM. Binimetinib activity in PIK3R1-mutant patient-derived xenografts (PDX) implanted into immunodeficient mice. J Clin Oncol. 2021;39:e13062. [DOI]

22.

Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, et al. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Cancer Res. 2020;80:4986–97. [DOI] [PubMed]

23.

Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, et al.; BLC2001 Study Group. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23:248–58. [DOI] [PubMed]

24.

Earp MA, Raghavan R, Li Q, Dai J, Winham SJ, Cunningham JM, et al. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. Oncotarget. 2017;8:46891–9. [DOI] [PubMed] [PMC]

25.

Blum AE, Venkitachalam S, Guo Y, Kieber-Emmons AM, Ravi L, Chandar AK, et al. RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res. 2016;76:5628–33. [DOI] [PubMed] [PMC]

26.

Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846. [DOI] [PubMed] [PMC]

27.

Zhu YC, Wang WX, Li XL, Xu CW, Chen G, Zhuang W, et al. Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing. J Thorac Oncol. 2019;14:e181–3. [DOI] [PubMed]

28.

Wang W, Lv W, Wang H, Xu Y, Yan J, Shen H, et al. A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma. Genes Dis. 2023;10:2241–4. [DOI] [PubMed] [PMC]

29.

Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, et al. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024;42:258–65. [DOI] [PubMed] [PMC]

30.

Aleksakhina SN, Ivantsov AO, Imyanitov EN. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution. Int J Mol Sci. 2024;25:4094. [DOI] [PubMed] [PMC]

31.

Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–75. [DOI] [PubMed] [PMC]